

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Raily Aesthetic Medicine International Holdings Limited

瑞麗醫美國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2135)

PROFIT WARNING

This announcement is made by Raily Aesthetic Medicine International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2024 (the “**Unaudited Management Accounts**”) and the information currently available to the Board, the Board expects the Group to record:

- (i) a revenue of approximately RMB117 million for the six months ended 30 June 2024 (six months ended 30 June 2023: revenue of approximately RMB98 million); and
- (ii) a loss attributable to owners of the parent of approximately RMB2 million for the six months ended 30 June 2024 (six months ended 30 June 2023: loss attributable to owners of the parent of approximately RMB2 million).

The Board considers that the continued loss is mainly attributable to the following:

- (a) in order to accelerate the Group’s research and development and production of medical equipment products, the Group increased its investment in the research and development activities of Suzhou Yonglan Biosciences Co., Ltd.* (蘇州詠藍生物醫藥科技有限公司) (“**Suzhou Yonglan**”), an indirect non wholly-owned subsidiary of the Company. For the six months ended 30 June 2024, administrative expenses and research and development expenses of Suzhou Yonglan amounted to approximately RMB2 million. Such expenses had not yet been recovered by the economic benefits to be derived therefrom during the reporting period; and

- (b) during the six months ended 30 June 2024, the share option expenses of the Group increased to approximately RMB4 million (six months ended 30 June 2023: approximately RMB3 million).

The information contained in this announcement is only based on the preliminary assessment by the Company's management according to the Unaudited Management Accounts and with reference to the information currently available, which have not been finalised or independently reviewed by the auditors of the Group or the audit committee of the Company, and are subject to amendments and adjustments where necessary. Shareholders of the Company and potential investors should refer to and review the interim results of the Company for the six months ended 30 June 2024, which are expected to be published by the end of August 2024.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Raily Aesthetic Medicine International Holdings Limited
FU Haishu
Chairman and Executive Director

Hangzhou, the PRC, 7 August 2024

As at the date of this announcement, the Board comprises Mr. Fu Haishu, Mr. Song Jianliang and Mr. Wang Ying as Executive Directors; and Mr. Cao Dequan, Ms. Yang Xiaofen and Mr. Liu Teng as Independent Non-executive Directors.

* *For identification purposes only*